Glioblastoma

Aldape, 2004, Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance, J Neuropathol Exp Neurol, 63, 700, 10.1093/jnen/63.7.700 Arita, 1994, Leptomeningeal dissemination of malignant gliomas. Incidence, diagnosis and outcome, Acta Neurochir (Wien), 126, 84, 10.1007/BF01476415 Awad, 1986, Leptomeningeal metastasis from supratentorial malignant gliomas, Neurosurgery, 19, 247, 10.1227/00006123-198608000-00010 Bady, 2012, MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status, Acta Neuropathol, 124, 547, 10.1007/s00401-012-1016-2 Bao, 2006, Glioma stem cells promote radioresistance by preferential activation of the DNA damage response, Nature, 444, 756, 10.1038/nature05236 Batchelor, 2013, Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma, J Clin Oncol, 31, 3212, 10.1200/JCO.2012.47.2464 Batchelor, 2014, Antiangiogenic therapy for glioblastoma: current status and future prospects, Clin Cancer Res, 20, 5612, 10.1158/1078-0432.CCR-14-0834 Beier, 2008, Temozolomide preferentially depletes cancer stem cells in glioblastoma, Cancer Res, 68, 5706, 10.1158/0008-5472.CAN-07-6878 Bloch, 2012, Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article, J Neurosurg, 117, 1032, 10.3171/2012.9.JNS12504 Bloch, 2015, Newly diagnosed glioblastoma patients treated with an autologous heat shock protein peptide vaccine: PD-L1 expression and response to therapy, J Clin Oncol Bondy, 2008, Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium, Cancer, 113, 1953, 10.1002/cncr.23741 Brada, 1992, Risk of second brain tumour after conservative surgery and radiotherapy for pituitary adenoma, Br Med J, 304, 1343, 10.1136/bmj.304.6838.1343 Brada, 2010, Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade glioma, J Clin Oncol, 28, 4601, 10.1200/JCO.2009.27.1932 Brahmer, 2015, Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer, N Engl J Med, 373, 123, 10.1056/NEJMoa1504627 Brandsma, 2008, Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas, Lancet Oncol, 9, 453, 10.1016/S1470-2045(08)70125-6 Butowski, 2006, Diagnosis and treatment of recurrent high-grade astrocytoma, J Clin Oncol, 24, 1273, 10.1200/JCO.2005.04.7522 Cancer Genome Atlas Research, 2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385 Capper, 2009, Monoclonal antibody specific for IDH1 R132H mutation, Acta Neuropathol, 118, 599, 10.1007/s00401-009-0595-z Chaichana, 2009, Long-term seizure outcomes in adult patients undergoing primary resection of malignant brain astrocytomas. Clinical article, J Neurosurg, 111, 282, 10.3171/2009.2.JNS081132 Chen, 2012, A restricted cell population propagates glioblastoma growth after chemotherapy, Nature, 488, 522, 10.1038/nature11287 Cheng, 2013, Glioblastoma stem cells generate vascular pericytes to support vessel function and tumor growth, Cell, 153, 139, 10.1016/j.cell.2013.02.021 Chinot, 2014, Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma, N Engl J Med, 370, 709, 10.1056/NEJMoa1308345 Collignon, 2004, Organ donors with malignant gliomas: an update, Am J Transplant, 4, 15, 10.1046/j.1600-6143.2003.00289.x Combs, 2007, Radiotherapeutic alternatives for previously irradiated recurrent gliomas, BMC Cancer, 7, 167, 10.1186/1471-2407-7-167 Connelly, 2007, Environmental risk factors for brain tumors, Curr Neurol Neurosci Rep, 7, 208, 10.1007/s11910-007-0032-4 de Wit, 2004, Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression, Neurology, 63, 535, 10.1212/01.WNL.0000133398.11870.9A Dhermain, 2004, Role of radiotherapy in recurrent gliomas, Bull Cancer, 91, 883 Djalilian, 1999, Radiographic incidence of multicentric malignant gliomas, Surg Neurol, 51, 554, 10.1016/S0090-3019(98)00054-8 Dziurzynski, 2012, Consensus on the role of human cytomegalovirus in glioblastoma, Neuro Oncol, 14, 246, 10.1093/neuonc/nor227 El Ali, 2011, ATP-binding cassette transporters and their roles in protecting the brain, Neuroscientist, 17, 423, 10.1177/1073858410391270 Ellingson, 2012, Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas, J Magn Reson Imaging, 35, 1472, 10.1002/jmri.23600 Ellingson, 2013, Probabilistic radiographic atlas of glioblastoma phenotypes, AJNR Am J Neuroradiol, 34, 533, 10.3174/ajnr.A3253 Ellis, 2008, VEGF-targeted therapy: mechanisms of anti-tumour activity, Nat Rev Cancer, 8, 579, 10.1038/nrc2403 Eriksson, 1998, Neurogenesis in the adult human hippocampus, Nat Med, 4, 1313, 10.1038/3305 Erlich, 1978, Spinal subarachnoid metastasis from primary intracranial glioblastoma multiforme, Cancer, 42, 2854, 10.1002/1097-0142(197812)42:6<2854::AID-CNCR2820420647>3.0.CO;2-4 Fan, 2013, EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma, Cancer Cell, 24, 438, 10.1016/j.ccr.2013.09.004 Fecci, 2014, Immunotherapy for primary brain tumors: no longer a matter of privilege, Clin Cancer Res, 20, 5620, 10.1158/1078-0432.CCR-14-0832 Folkman, 1971, Tumor angiogenesis: therapeutic implications, N Engl J Med, 285, 1182, 10.1056/NEJM197111182852108 Friedman, 2009, Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma, J Clin Oncol, 27, 4733, 10.1200/JCO.2008.19.8721 Gallego Perez-Larraya, 2011, Temozolomide in elderly patients with newly diagnosed glioblastoma and poor performance status: an ANOCEF phase II trial, J Clin Oncol, 29, 3050, 10.1200/JCO.2011.34.8086 Gilbert, 2013, Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial, J Clin Oncol, 31, 4085, 10.1200/JCO.2013.49.6968 Gilbert, 2014, A randomized trial of bevacizumab for newly diagnosed glioblastoma, N Engl J Med, 370, 699, 10.1056/NEJMoa1308573 Gilbertson, 2007, Making a tumour's bed: glioblastoma stem cells and the vascular niche, Nat Rev Cancer, 7, 733, 10.1038/nrc2246 Grabb, 1992, Dissemination of supratentorial malignant gliomas via the cerebrospinal fluid in children, Neurosurgery, 30, 64, 10.1227/00006123-199201000-00012 Grothey, 2009, Targeting angiogenesis: progress with anti-VEGF treatment with large molecules, Nat Rev Clin Oncol, 6, 507, 10.1038/nrclinonc.2009.110 Han, 2010, Primary gliosarcoma: key clinical and pathologic distinctions from glioblastoma with implications as a unique oncologic entity, J Neurooncol, 96, 313, 10.1007/s11060-009-9973-6 Hegi, 2005, MGMT gene silencing and benefit from temozolomide in glioblastoma, N Engl J Med, 352, 997, 10.1056/NEJMoa043331 Hegi, 2012, Epidermal growth factor receptor: a re-emerging target in glioblastoma, Curr Opin Neurol, 25, 774, 10.1097/WCO.0b013e328359b0bc Heimberger, 2005, Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients, Clin Cancer Res, 11, 1462, 10.1158/1078-0432.CCR-04-1737 Herrlinger, 2004, Leptomeningeal metastasis: survival and prognostic factors in 155 patients, J Neurol Sci, 223, 167, 10.1016/j.jns.2004.05.008 Hodi, 2010, Improved survival with ipilimumab in patients with metastatic melanoma, N Engl J Med, 363, 711, 10.1056/NEJMoa1003466 Humphrey, 1990, Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma, Proc Natl Acad Sci U S A, 87, 4207, 10.1073/pnas.87.11.4207 Interphone Study Group, 2010, Brain tumour risk in relation to mobile telephone use: results of the INTERPHONE international case-control study, Int J Epidemiol, 39, 675, 10.1093/ije/dyq079 Karsy, 2012, Established and emerging variants of glioblastoma multiforme: review of morphological and molecular features, Folia Neuropathol, 50, 301, 10.5114/fn.2012.32361 Kaufmann, 2014, Glioma virus therapies between bench and bedside, Neuro Oncol, 16, 334, 10.1093/neuonc/not310 Keime-Guibert, 2007, Radiotherapy for glioblastoma in the elderly, N Engl J Med, 356, 1527, 10.1056/NEJMoa065901 Kerkhof, 2013, Effect of valproic acid on seizure control and on survival in patients with glioblastoma multiforme, Neuro Oncol, 15, 961, 10.1093/neuonc/not057 Kickingereder, 2014, Primary central nervous system lymphoma and atypical glioblastoma: multiparametric differentiation by using diffusion-, perfusion-, and susceptibility-weighted MR imaging, Radiology, 272, 843, 10.1148/radiol.14132740 Kono, 2001, The role of diffusion-weighted imaging in patients with brain tumors, AJNR Am J Neuroradiol, 22, 1081 Korshunov, 2007, Gains at the 1p36 chromosomal region are associated with symptomatic leptomeningeal dissemination of supratentorial glioblastomas, Am J Clin Pathol, 127, 585, 10.1309/DE4LNX3YMACCC1ER Kozak, 2009, Giant cell glioblastoma: a glioblastoma subtype with distinct epidemiology and superior prognosis, Neuro Oncol, 11, 833, 10.1215/15228517-2008-123 Kozak, 2009, Adult gliosarcoma: epidemiology, natural history, and factors associated with outcome, Neuro Oncol, 11, 183, 10.1215/15228517-2008-076 Kreisl, 2009, Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma, J Clin Oncol, 27, 740, 10.1200/JCO.2008.16.3055 Kubben, 2011, Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review, Lancet Oncol, 12, 1062, 10.1016/S1470-2045(11)70130-9 La Fougere, 2011, Molecular imaging of gliomas with PET: opportunities and limitations, Neuro Oncol, 13, 806, 10.1093/neuonc/nor054 Labussiere, 2014, TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations, Br J Cancer, 111, 2024, 10.1038/bjc.2014.538 Lacroix, 2001, A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival, J Neurosurg, 95, 190, 10.3171/jns.2001.95.2.0190 Lai, 2011, Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme, J Clin Oncol, 29, 142, 10.1200/JCO.2010.30.2729 Laperriere, 2013, Optimal management of elderly patients with glioblastoma, Cancer Treat Rev, 39, 350, 10.1016/j.ctrv.2012.05.008 Lathia, 2010, Integrin alpha 6 regulates glioblastoma stem cells, Cell Stem Cell, 6, 421, 10.1016/j.stem.2010.02.018 Law, 2003, Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging, AJNR Am J Neuroradiol, 24, 1989 Lee, 2012, Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02, Neuro Oncol, 14, 1511, 10.1093/neuonc/nos264 Lindsay, 2002, Spinal leptomeningeal metastases following glioblastoma multiforme treated with radiotherapy, J Clin Neurosci, 9, 725, 10.1054/jocn.2002.1079 Louis, 2007, The 2007 WHO classification of tumours of the central nervous system, Acta Neuropathol, 114, 97, 10.1007/s00401-007-0243-4 Macdonald, 1990, Response criteria for phase II studies of supratentorial malignant glioma, J Clin Oncol, 8, 1277, 10.1200/JCO.1990.8.7.1277 Malmstrom, 2012, Temozolomide versus standard 6-week radiotherapy versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial, Lancet Oncol, 13, 916, 10.1016/S1470-2045(12)70265-6 Mashimo, 2014, Acetate is a bioenergetic substrate for human glioblastoma and brain metastases, Cell, 159, 1603, 10.1016/j.cell.2014.11.025 Minniti, 2005, Risk of second brain tumor after conservative surgery and radiotherapy for pituitary adenoma: update after an additional 10 years, J Clin Endocrinol Metab, 90, 800, 10.1210/jc.2004-1152 Mitchell, 2015, Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients, Nature, 519, 366, 10.1038/nature14320 Neglia, 2006, New primary neoplasms of the central nervous system in survivors of childhood cancer: a report from the Childhood Cancer Survivor Study, J Natl Cancer Inst, 98, 1528, 10.1093/jnci/djj411 Nghiemphu, 2009, Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience, Neurology, 72, 1217, 10.1212/01.wnl.0000345668.03039.90 Nishikawa, 2004, Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma, Brain Tumor Pathol, 21, 53, 10.1007/BF02484510 Noushmehr, 2010, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell, 17, 510, 10.1016/j.ccr.2010.03.017 Nunes, 2003, Identification and isolation of multipotential neural progenitor cells from the subcortical white matter of the adult human brain, Nat Med, 9, 439, 10.1038/nm837 Ohgaki, 2010, Nervous system tumors associated with familial tumor syndromes, Curr Opin Neurol, 23, 583, 10.1097/WCO.0b013e3283405b5f Ostrom, 2011, Current state of our knowledge on brain tumor epidemiology, Curr Neurol Neurosci Rep, 11, 329, 10.1007/s11910-011-0189-8 Ostrom, 2014, CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007–2011, Neuro Oncol, 16, iv1, 10.1093/neuonc/nou223 Ostrom, 2014, The epidemiology of glioma in adults: a “state of the science” review, Neuro Oncol, 16, 896, 10.1093/neuonc/nou087 Ostrom, 2015, Alex's Lemonade Stand Foundation infant and childhood primary brain and central nervous system tumors diagnosed in the United States in 2007–2011, Neuro Oncol, 16, x1, 10.1093/neuonc/nou327 Ozawa, 2014, Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma, Cancer Cell, 26, 288, 10.1016/j.ccr.2014.06.005 Park, 2010, Scale to predict survival after surgery for recurrent glioblastoma multiforme, J Clin Oncol, 28, 3838, 10.1200/JCO.2010.30.0582 Parsons, 2008, An integrated genomic analysis of human glioblastoma multiforme, Science, 321, 1807, 10.1126/science.1164382 Patel, 2014, Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma, Science, 344, 1396, 10.1126/science.1254257 Phillips, 2006, Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis, Cancer Cell, 9, 157, 10.1016/j.ccr.2006.02.019 Pietras, 2014, Osteopontin-CD44 signaling in the glioma perivascular niche enhances cancer stem cell phenotypes and promotes aggressive tumor growth, Cell Stem Cell, 14, 357, 10.1016/j.stem.2014.01.005 Reardon, 2015, 107 ReACT: overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma, Neurosurgery, 62, 198, 10.1227/01.neu.0000467069.86811.3f Ribas, 2013, Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma, J Clin Oncol, 31, 616, 10.1200/JCO.2012.44.6112 Ricci-Vitiani, 2010, Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells, Nature, 468, 824, 10.1038/nature09557 Rizvi, 2015, Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial, Lancet Oncol, 16, 257, 10.1016/S1470-2045(15)70054-9 Roa, 2004, Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial, J Clin Oncol, 22, 1583, 10.1200/JCO.2004.06.082 Rohle, 2013, An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells, Science, 340, 626, 10.1126/science.1236062 Ron, 1988, Tumors of the brain and nervous system after radiotherapy in childhood, N Engl J Med, 319, 1033, 10.1056/NEJM198810203191601 Rygh, 2008, Comparison of navigated 3D ultrasound findings with histopathology in subsequent phases of glioblastoma resection, Acta Neurochir (Wien), 150, 1033, 10.1007/s00701-008-0017-3 Sadetzki, 2005, Long-term follow-up for brain tumor development after childhood exposure to ionizing radiation for tinea capitis, Radiat Res, 163, 424, 10.1667/RR3329 Sampson, 2010, Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma, J Clin Oncol, 28, 4722, 10.1200/JCO.2010.28.6963 Sanai, 2004, Unique astrocyte ribbon in adult human brain contains neural stem cells but lacks chain migration, Nature, 427, 740, 10.1038/nature02301 Sanai, 2005, Neural stem cells and the origin of gliomas, N Engl J Med, 353, 811, 10.1056/NEJMra043666 Sanai, 2011, An extent of resection threshold for newly diagnosed glioblastomas, J Neurosurg, 115, 3, 10.3171/2011.2.JNS10998 Sandmann, 2015, Patients with proneural glioblastoma may derive overall survival benefit from the addition of bevacizumab to first-line radiotherapy and temozolomide: retrospective analysis of the AVAglio trial, J Clin Oncol, 33, 2735, 10.1200/JCO.2015.61.5005 Schumacher, 2014, A vaccine targeting mutant IDH1 induces antitumour immunity, Nature, 512, 324, 10.1038/nature13387 Schuster, 2015, A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study, Neuro Oncol, 17, 854, 10.1093/neuonc/nou348 Schweitzer, 2001, Extraneural metastases of primary brain tumors, J Neurooncol, 53, 107, 10.1023/A:1012245115209 Scott, 2011, Effectiveness of radiotherapy for elderly patients with glioblastoma, Int J Radiat Oncol Biol Phys, 81, 206, 10.1016/j.ijrobp.2010.04.033 Shinojima, 2003, Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme, Cancer Res, 63, 6962 Simpson, 1993, Influence of location and extent of surgical resection on survival of patients with glioblastoma multiforme: results of three consecutive Radiation Therapy Oncology Group (RTOG) clinical trials, Int J Radiat Oncol Biol Phys, 26, 239, 10.1016/0360-3016(93)90203-8 Singh, 2004, Identification of human brain tumour initiating cells, Nature, 432, 396, 10.1038/nature03128 Son, 2009, SSEA-1 is an enrichment marker for tumor-initiating cells in human glioblastoma, Cell Stem Cell, 4, 440, 10.1016/j.stem.2009.03.003 Sottoriva, 2013, Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics, Proc Natl Acad Sci U S A, 110, 4009, 10.1073/pnas.1219747110 Stummer, 2006, Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial, Lancet Oncol, 7, 392, 10.1016/S1470-2045(06)70665-9 Stummer, 2008, Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias, Neurosurgery, 62, 564, 10.1227/01.neu.0000317304.31579.17 Stupp, 2005, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma, N Engl J Med, 352, 987, 10.1056/NEJMoa043330 Stupp, 2012, NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a randomised phase III trial of a novel treatment modality, Eur J Cancer, 48, 2192, 10.1016/j.ejca.2012.04.011 Stupp, 2014, Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial, Lancet Oncol, 15, 1100, 10.1016/S1470-2045(14)70379-1 Stupp, 2014, Interim analysis of the EF-14 trial: a prospective, multi-center trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM, Neuro Oncol, 16, v167, 10.1093/neuonc/nou265.40 Sturm, 2012, Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma, Cancer Cell, 22, 425, 10.1016/j.ccr.2012.08.024 Suchorska, 2015, Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastoma results from the DIRECTOR trial, Neurosurgery, 62, 209, 10.1227/01.neu.0000467098.06935.3d Taal, 2014, Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial, Lancet Oncol, 15, 943, 10.1016/S1470-2045(14)70314-6 Taphoorn, 2005, Health-related quality of life in patients with glioblastoma: a randomised controlled trial, Lancet Oncol, 6, 937, 10.1016/S1470-2045(05)70432-0 Taphoorn, 2015, Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma, J Clin Oncol, 33, 2166, 10.1200/JCO.2014.60.3217 Thomas, 2012, Immunotherapy for the treatment of glioblastoma, Cancer J, 18, 59, 10.1097/PPO.0b013e3182431a73 Thomas, 2014, Emerging therapies for glioblastoma, JAMA Neurol, 71, 1437, 10.1001/jamaneurol.2014.1701 Turcan, 2012, IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype, Nature, 483, 479, 10.1038/nature10866 van Breemen, 2009, Efficacy of anti-epileptic drugs in patients with gliomas and seizures, J Neurol, 256, 1519, 10.1007/s00415-009-5156-9 Verhaak, 2010, Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1, Cancer Cell, 17, 98, 10.1016/j.ccr.2009.12.020 Wang, 2010, Glioblastoma stem-like cells give rise to tumour endothelium, Nature, 468, 829, 10.1038/nature09624 Warrens, 2012, Advising potential recipients on the use of organs from donors with primary central nervous system tumors, Transplantation, 93, 348, 10.1097/TP.0b013e31823f7f47 Watson, 2010, How safe is it to transplant organs from deceased donors with primary intracranial malignancy? An analysis of UK Registry data, Am J Transplant, 10, 1437, 10.1111/j.1600-6143.2010.03130.x Weber, 2006, Diagnostic performance of spectroscopic and perfusion MRI for distinction of brain tumors, Neurology, 66, 1899, 10.1212/01.wnl.0000219767.49705.9c Weller, 2010, MGMT promoter methylation in malignant gliomas: ready for personalized medicine?, Nat Rev Neurol, 6, 39, 10.1038/nrneurol.2009.197 Weller, 2013, Standards of care for treatment of recurrent glioblastoma – are we there yet?, Neuro Oncol, 15, 4, 10.1093/neuonc/nos273 Weller, 2014, EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma, Lancet Oncol, 15, e395, 10.1016/S1470-2045(14)70011-7 Weller, 2015, Glioma, Nat Rev Dis Primers, 10.1038/nrdp.2015.17 Weller, 2015, MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial, Clin Cancer Res, 21, 2057, 10.1158/1078-0432.CCR-14-2737 Wen, 2010, Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group, J Clin Oncol, 28, 1963, 10.1200/JCO.2009.26.3541 Wen, 2014, A randomized double blind placebo-controlled phase 2 trial of dendritic cell (DC) vaccine ICT-107 following standard treatment in newly diagnosed patients with GBM, Neuro Oncol, 16, v8, 10.1093/neuonc/nou237.59 Wen, 2014, Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02, Neuro Oncol, 16, 567, 10.1093/neuonc/not247 Wick, 2014, CMV infection and glioma, a highly controversial concept struggling in the clinical arena, Neuro Oncol, 16, 332, 10.1093/neuonc/nou002 Wick, 2005, Pharmacotherapy of epileptic seizures in glioma patients: who, when, why and how long?, Onkologie, 28, 391, 10.1159/000086375 Wick, 2010, Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma, J Clin Oncol, 28, 1168, 10.1200/JCO.2009.23.2595 Wick, 2012, Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial, Lancet Oncol, 13, 707, 10.1016/S1470-2045(12)70164-X Wick, 2014, Radiation therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus chemoirradiation with temozolomide in newly diagnosed glioblastoma without methylation of the MGMT gene promoter, J Clin Oncol, 32, 5s, 10.1200/jco.2014.32.15_suppl.2003 Wilson, 1979, Current concepts in cancer: brain tumors, N Engl J Med, 300, 1469, 10.1056/NEJM197906283002605 Wolchok, 2013, Nivolumab plus ipilimumab in advanced melanoma, N Engl J Med, 369, 122, 10.1056/NEJMoa1302369 Yan, 2009, IDH1 and IDH2 mutations in gliomas, N Engl J Med, 360, 765, 10.1056/NEJMoa0808710 Yan, 2013, The evolving landscape of glioblastoma stem cells, Curr Opin Neurol, 26, 701, 10.1097/WCO.0000000000000032 Yuile, 2006, Survival of glioblastoma patients related to presenting symptoms, brain site and treatment variables, J Clin Neurosci, 13, 747, 10.1016/j.jocn.2005.10.011